- According to estimates from 14 analysts, Summit Therapeutics Inc. stock's average price target has fallen from $29.84 to $29.06, with forecasts ranging from $9.8 to $41 per share
- Based on the Jul. 23 closing price, the updated target implies approximately 94% potential upside
- Consensus rating remains at “Buy” across 17 covering analysts, with 11 Buys, 5 Holds and 1 Sells
Explore more price target data and ratings for Summit Therapeutics Inc. on the , and track all previous and future analyst recommendations for Summit Therapeutics Inc. in the dedicated .
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.